September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Role of V-domain Ig suppressor of T cell activation (VISTA) in Anterior Chamber Associated Immune Deviation
Author Affiliations & Notes
  • Tomoyuki Kunishige
    opthalmology, Nippon Medical School, Bunkyo-ku, Japan
  • Hiroko Taniguchi
    opthalmology, Nippon Medical School, Bunkyo-ku, Japan
  • Tatsukuni Ohno
    Tokyo Medical Dental University, Tokyo, Japan
  • MIyuki Azuma
    Tokyo Medical Dental University, Tokyo, Japan
  • Junko Hori
    opthalmology, Nippon Medical School, Bunkyo-ku, Japan
  • Footnotes
    Commercial Relationships   Tomoyuki Kunishige, None; Hiroko Taniguchi, None; Tatsukuni Ohno, None; MIyuki Azuma, None; Junko Hori, None
  • Footnotes
    Support  Grant-in-Aid for Scientific Research(C) from the Japan Society for the Promotion of Science
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 319. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tomoyuki Kunishige, Hiroko Taniguchi, Tatsukuni Ohno, MIyuki Azuma, Junko Hori; Role of V-domain Ig suppressor of T cell activation (VISTA) in Anterior Chamber Associated Immune Deviation. Invest. Ophthalmol. Vis. Sci. 2016;57(12):319.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : V-domain Ig suppressor of T cell activation (VISTA) is a novel and structurally distinct Ig superfamily inhibitory ligand. We have previously demonstrated that survival of corneal allografts in the recipients treated with anti-VISTA mAb was significantly less than that of the control, and that VISTA plays an important role on induction of alloantigen-specific anterior chamber associated immune deviation (ACAID). The purpose of the present study was to determine the mechanism of VISTA-mediated immune suppression in ACAID.

Methods : Alloantigen-specific ACAID model in mice was used. We administrated BALB/c mice intraperitoneally with 0.2 mg of anti-VISTA monoclonal antibody or control rat IgG, three times a week for 3 weeks after anterior chamber injection of allogeneic spleen cells. After induction of ACAID, expressions of CD4, CD8 and CD103 in the spleen of ACAID model mice were examined by flow cytometry.

Results : The proportions of CD8+ T cells and CD8+ CD103+ T cells (CD8+ T regulatory cells) in the spleen cells of ACAID model mice treated with anti-VISTA mAb were significantly lower than that of control. No significant differences were observed between the proportions of CD4+ T cells in the spleen cells of ACAID model mice treated with anti-VISTA mAb and that of control.

Conclusions : VISTA may play a role on allo-specific ACAID by inducing CD8+ T regulatory cells in spleen.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×